Decade after first approval, bispecifics on the precipice of going mainstream

Back to School 2024 identifies the target classes emerging in inflammation and immunology, and the technologies used to find them

Plus: GSK licenses WuXi Biologics bispecific, Acelyrin adds thyroid eye asset via ValenzaBio takeout, HighTide, Metagenomi, Synaffix-Amgen, AstraZeneca and more

Jazz pays $50M up front for rights to HER2-targeting bispecific, would owe more than 6x more to retain them after first pivotal readout

Roche to pay $250M for Good Therapeutics’ PD-1-regulated IL-2 program, leaving new company Bonum Therapeutics to develop the platform

Up next after Saphnelo are late-stage programs from Idorsia, RemeGen 

One implication of the recent Yale study linking autoantibody production to the development of long COVID is that treatment with therapies directed at B cells or antibody clearance might prove useful